Angiotensin Receptor-Neprilysin Inhibition: New Therapeutic Concept for the Management of Chronic Heart Failure: Development, Clinical Implications, and Future Perspectives

Ofer Havakuk, Uri Elkayam

Research output: Contribution to journalReview articlepeer-review

Abstract

The novel combination sacubitril/valsartan represents a new therapeutic approach in the management of heart failure. With the simultaneous blockage of the enzyme neprilysin (by sacubitril) and angiotensin II receptors (by valsartan), this combination reduces the degradation of natriuretic peptides and other counterregulatory peptide systems while avoiding the deleterious effect of angiotensin II receptors activation and thereby encompasses a beneficial impact of 2 important neurohormonal pathways activated in heart failure. As opposed to previously tested neprilysin inhibitors, sacubitril/valsartan represents a more effective method in reducing morbidity and mortality in heart failure, while preserving a safety profile comparable to well-established, standard, angiotensin-converting enzyme inhibitor's therapy.

Original languageEnglish
Pages (from-to)356-364
Number of pages9
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume22
Issue number4
DOIs
StatePublished - 1 Jul 2017
Externally publishedYes

Keywords

  • heart failure
  • neprilysin
  • sacubitril/valsartan

Fingerprint

Dive into the research topics of 'Angiotensin Receptor-Neprilysin Inhibition: New Therapeutic Concept for the Management of Chronic Heart Failure: Development, Clinical Implications, and Future Perspectives'. Together they form a unique fingerprint.

Cite this